The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Abdulazeez Salawu
No Relationships to Disclose
 
Marc Oliva Bernal
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Mirati Therapeutics
Travel, Accommodations, Expenses - MSD Oncology
Other Relationship - Bristol-Myers Squibb; Merck
 
Daniel Vilarim Araujo
Honoraria - GlaxoSmithKline
 
Zhihui (Amy) Liu
No Relationships to Disclose
 
Rachel Chen
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)